Imagion Biosystems gives notice that, on 20 October 2020 the Company issued 2,401,900 fully paid ordinary shares (Shares) in the Company as the result of shareholder exercising their options in the Company.
Read the notice.
Imagion Initiates Manufacturing of MagSense® Drug for Phase 2 Clinical Study on HER2+ Breast Cancer
February 19, 2025
MELBOURNE – Imagion Biosystems (Company) (ASX : IBX), a company dedicated to improving healthcare outcomes through the early detection of cancer, is pleased to announce